Menu
Back to Journals » Drug Design, Development and Therapy » Volume 5 » default
Drug Design, Development and Therapy
ISSN: 1177-8881
- View all (3985)
- Volume 17, 2023 (229)
- Volume 16, 2022 (316)
- Volume 15, 2021 (399)
- Volume 14, 2020 (477)
- Volume 13, 2019 (387)
- Volume 12, 2018 (382)
- Volume 11, 2017 (330)
- Volume 10, 2016 (374)
- Volume 9, 2015 (543)
- Volume 8, 2014 (231)
- Volume 7, 2013 (143)
- Volume 6, 2012 (42)
- Volume 5, 2011 (40)
- Volume 4, 2010 (35)
- Volume 3, 2009 (27)
- Volume 2, 2008 (29)
- Volume 1, 2007 (1)
Archive: Volume 5, 2011
Profile of ipilimumab and its role in the treatment of metastatic melanoma
Patel SP, Woodman SE
Drug Design, Development and Therapy 2011, 5:489-495
Published Date: 16 December 2011
Corrigendum
Escobar-Chávez JJ, Domínguez-Delgado CL, Rodríguez-Cruz IM
Drug Design, Development and Therapy 2011, 5:487-488
Published Date: 28 November 2011
Crizotinib: a novel and first-in-class multitargeted tyrosine kinase inhibitor for the treatment of anaplastic lymphoma kinase rearranged nonsmall cell lung cancer and beyond
Ou SH
Drug Design, Development and Therapy 2011, 5:471-485
Published Date: 23 November 2011
The influence of operational parameters and feed preparation in a convective batch ribbon powder mixer
Yeow ST, Shahar A, Abdul Aziz N, Anuar MS, Yusof YA, Taip FS
Drug Design, Development and Therapy 2011, 5:465-469
Published Date: 14 November 2011
Bioequivalence of oxymorphone extended release and crush-resistant oxymorphone extended release
Benedek IH, Jobes J, Xiang Q, Fiske WD
Drug Design, Development and Therapy 2011, 5:455-463
Published Date: 31 October 2011
Clinical utility of clodronate in the prevention and management of osteoporosis in patients intolerant of oral bisphosphonates
Muratore M, Quarta E, Grimaldi A, Calcagnile F, Quarta L
Drug Design, Development and Therapy 2011, 5:445-454
Published Date: 19 October 2011
Future prospects in the treatment of erectile dysfunction: focus on avanafil
Alwaal A, Al-Mannie R, Carrier S
Drug Design, Development and Therapy 2011, 5:435-443
Published Date: 18 October 2011
Bioequivalence assessment of two formulations of ibuprofen
Al-Talla ZA, Akrawi SH, Tolley LT, Sioud SH, Zaater MF, Emwas AHM
Drug Design, Development and Therapy 2011, 5:427-433
Published Date: 19 October 2011
Investigation of the antibacterial activity of pioglitazone
Masadeh MM, Mhaidat NM, Al-Azzam SI, Alzoubi KH
Drug Design, Development and Therapy 2011, 5:421-425
Published Date: 27 September 2011
Emerging options in growth hormone therapy: an update
Kemp SF, Frindik JP
Drug Design, Development and Therapy 2011, 5:411-419
Published Date: 30 August 2011
Successful mobilization of peripheral blood stem cells in children with cancer using plerixafor (Mozobil™) and granulocyte-colony stimulating factor
Avramova BE, Yordanova MN, Konstantinov DN, Bobev DG
Drug Design, Development and Therapy 2011, 5:407-409
Published Date: 26 August 2011
Why has it been so difficult to prove the efficacy of alpha-1-antitrypsin replacement therapy? Insights from the study of disease pathogenesis
Dickens JA, Lomas DA
Drug Design, Development and Therapy 2011, 5:391-405
Published Date: 17 August 2011
Five-day regimen of intramuscular or subcutaneous self-administered adrenocorticotropic hormone gel for acute exacerbations of multiple sclerosis: a prospective, randomized, open-label pilot trial
Simsarian JP, Saunders C, Smith DM
Drug Design, Development and Therapy 2011, 5:381-389
Published Date: 11 July 2011
Primary prevention of coronary heart disease: integration of new data, evolving views, revised goals, and role of rosuvastatin in management. A comprehensive survey
Kones R
Drug Design, Development and Therapy 2011, 5:325-380
Published Date: 13 June 2011
Effect of surfactant and surfactant blends on pseudoternary phase diagram behavior of newly synthesized palm kernel oil esters
Mahdi ES, Sakeena MH, Abdulkarim MF, Abdullah GZ, Sattar MA, Noor AM
Drug Design, Development and Therapy 2011, 5:311-323
Published Date: 1 June 2011
Flavonoids targeting of IκB phosphorylation abrogates carcinogen-induced MMP-9 and COX-2 expression in human brain endothelial cells
Tahanian E, Sanchez LA, Shiao TC, Roy R, Annabi B
Drug Design, Development and Therapy 2011, 5:299-309
Published Date: 13 May 2011
Place of pitavastatin in the statin armamentarium: promising evidence for a role in diabetes mellitus
Kawai Y, Sato-Ishida R, Motoyama A, Kajinami K
Drug Design, Development and Therapy 2011, 5:283-297
Published Date: 11 May 2011
Current difficulties and recent advances in bypass therapy for the management of hemophilia with inhibitors: a new and practical formulation of recombinant factor VIIa
Butros L, Boayue K, Mathew P
Drug Design, Development and Therapy 2011, 5:275-282
Published Date: 12 May 2011
Development of oral immunomodulatory agents in the management of multiple sclerosis
Nicholas R, Giannetti P, Alsanousi A, Friede T, Muraro PA
Drug Design, Development and Therapy 2011, 5:255-274
Published Date: 10 May 2011
Available and emerging treatments for Parkinson’s disease: a review
Hickey PT, Stacy MA
Drug Design, Development and Therapy 2011, 5:241-254
Published Date: 2 May 2011
Emerging strategies and therapies for treatment of Paget’s disease of bone
Michou L, Brown JP
Drug Design, Development and Therapy 2011, 5:225-239
Published Date: 26 April 2011
Targeting nicotine addiction: the possibility of a therapeutic vaccine
Escobar-Chávez JJ, Domínguez-Delgado CL, Rodríguez-Cruz IM
Drug Design, Development and Therapy 2011, 5:211-224
Published Date: 18 April 2011
Current and emerging drugs for the treatment of inflammatory bowel disease
Triantafillidis JK, Merikas E, Georgopoulos F
Drug Design, Development and Therapy 2011, 5:185-210
Published Date: 6 April 2011
Corrigendum
Channing J Paller, Emmanuel S Antonarakis
Drug Design, Development and Therapy 2011, 5:183-184
Published Date: 21 March 2011
Drug discovery and development for neglected diseases: the DNDi model
Eric Chatelain, Jean-Robert Ioset
Drug Design, Development and Therapy 2011, 5:175-181
Published Date: 16 March 2011
Update on role of agalsidase alfa in management of Fabry disease
Uma Ramaswami
Drug Design, Development and Therapy 2011, 5:155-173
Published Date: 14 March 2011
Treatment of nephrotic syndrome with adrenocorticotropic hormone (ACTH) gel
Andrew S Bomback, James A Tumlin, Joel Baranski, et al
Drug Design, Development and Therapy 2011, 5:147-153
Published Date: 14 March 2011
Paliperidone extended-release: does it have a place in antipsychotic therapy?
Maximilian Gahr, Markus A Kölle, Carlos Schönfeldt-Lecuona, et al
Drug Design, Development and Therapy 2011, 5:125-146
Published Date: 11 March 2011
Cabazitaxel: a novel second-line treatment for metastatic castration-resistant prostate cancer
Channing J Paller, Emmanuel S Antonarakis
Drug Design, Development and Therapy 2011, 5:117-124
Published Date: 10 March 2011
Maintaining remission in ulcerative colitis – role of once daily extended-release mesalamine
Lilliana Oliveira, Russell D Cohen
Drug Design, Development and Therapy 2011, 5:111-116
Published Date: 27 February 2011
The use of serotonergic drugs to treat obesity – is there any hope?
Nicholas T Bello, Nu-Chu Liang
Drug Design, Development and Therapy 2011, 5:95-109
Published Date: 10 February 2011
Cefditoren in upper and lower community-acquired respiratory tract infections
Francisco Soriano, María-José Giménez, Lorenzo Aguilar
Drug Design, Development and Therapy 2011, 5:85-94
Published Date: 9 February 2011
Comparison of effects of alcaftadine and olopatadine on conjunctival epithelium and eosinophil recruitment in a murine model of allergic conjunctivitis
Santa J Ono, Keith Lane
Drug Design, Development and Therapy 2011, 5:77-84
Published Date: 8 February 2011
Illicit methylphenidate use among Iranian medical students: prevalence and knowledge
Afshin Habibzadeh Mahasti Alizadeh Ayoub Malek, et al
Drug Design, Development and Therapy 2011, 5:71-76
Published Date: 3 February 2011
Abatacept in the treatment of polyarticular JIA: development, clinical utility, and place in therapy
Ofra Goldzweig, Philip J Hashkes
Drug Design, Development and Therapy 2011, 5:61-70
Published Date: 26 January 2011
When is high-dose intravenous iron repletion needed? Assessing new treatment options
David Gozzard
Drug Design, Development and Therapy 2011, 5:51-60
Published Date: 20 January 2011
Comparative assessment of biologics in treatment of psoriasis: drug design and clinical effectiveness of ustekinumab
Ignacio Garcia-Valladares, Raquel Cuchacovich, Luis R Espinoza
Drug Design, Development and Therapy 2011, 5:41-49
Published Date: 10 January 2011
Dronedarone: current evidence for its safety and efficacy in the management of atrial fibrillation
Patrick A Schweizer, Rüdiger Becker, Hugo A Katus, et al
Drug Design, Development and Therapy 2011, 5:27-39
Published Date: 6 January 2011
Current progress in the development of a prophylactic vaccine for HIV-1
Lena J Gamble, Qiana L Matthews
Drug Design, Development and Therapy 2011, 5:9-26
Published Date: 22 December 2010
The use of lorcaserin in the management of obesity: a critical appraisal
Bo Bai, Yu Wang
Drug Design, Development and Therapy 2011, 5:1-7
Published Date: 20 December 2010